Clinical trial · Observational
Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash
NCT06665490CI-TRIAL-00110125enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this pilot study of patients with mycosis fungoides, the most common form of CTCL, we propose to primarily evaluate the impact of daily use of the CLn Body Wash (dilute sodium hypochlorite (0.006% NaOCl)) on the microbiota of CTCL lesions. Should dilute sodium hypochlorite body wash improve the microbiome of MF, reducing the abundance of S. aureus, future, larger studies can more fully evaluate the impact on pruritus, erythema, scaling, disease evolution and its role in CTCL management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous T Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CLn Body Wash | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Mycosis Fungoides patients
- description
- Patients with mycosis fungoides will be enrolled at Northwestern Memorial Hospital Dermatology
- interventionNames
- Other: CLn Body Wash
Primary outcomes (1)
- measure
- Change of S. aureus skin microbiome
- timeFrame
- 8 weeks
- description
- Change of S. aureus relative abundance between baseline (Week 0) and Week 8.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Adults ages 18-89 years of age with active mycosis fungoides. * Patients with concurrent and prior malignancies are allowed as long as any concurrent malignancy does not directly involve the same skin site. Exclusion Criteria: * Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics, pregnant persons, or persons with potential of becoming pregnant or are/will be breastfeeding * Patients that have initiated a new skin-directed therapy over the past month.
References
Publications (0)
Data not yet available
No reference posted for this study.